Bio-Rad Laboratories, Inc.

Ladies and gentlemen, thank you for standing by. Welcome to the Q1 2021 Bio-Rad Laboratories Incorporated Earnings Conference Call. At this time, all participants are in the listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question at this time, you will need to press star, then the number 1 on your telephone keypad. If your question has been answered and you would like to withdraw, you can press the hash key or the pound key. Thank you. I'd like to turn it over to Mr. Ron Hutton. You may begin the conference, sir.

Thank you. Good afternoon and thank you all for joining us. Today we will review the first quarter results of 2021. With me on the phone today are Norman Schwartz, our Chief Executive Officer, Ilan Daskal, Executive Vice President and Chief Financial Officer, Andy Last, Executive Vice President and Chief Operating Officer, Annette Tumalo, President of the Life Science Group, and Dara Wright, President of the Clinical Diagnostics Group. Before we begin our review, I would like to caution everyone that we will be making forward-looking statements about management's goals, plans, and expectations, our future financial performance, and other matters. These statements are based on assumptions and expectations of future events that are subject to risks and uncertainties. Included in these forward-looking statements are statements regarding the impact of the COVID-19 pandemic on Bio-Rad's results and operations and steps Bio-Rad is taking in response to the pandemic. Our actual results may differ materially from these plans and expectations and the impact and the duration of the COVID-19 pandemic is unknown. We cannot be certain that Bio-Rad's responses to the pandemic will be successful, that the demand for Bio-Rad's COVID-19 related products is sustainable, or that Bio-Rad will be able to meet this demand. You should not place undue reliance on these forward-looking statements, and I encourage you to review our filings with the SEC where we discuss in detail the risk factors in our business. The company does not intend to update any forward-looking statements made during the call today. Our remarks today will also include references to non-GAAP net income and non-GAAP diluted income per share, which are financial measures that are not defined under generally accepted accounting principles. Investors should review the reconciliation of these non-GAAP measures to the comparable GAAP results contained in our earnings release. I will now turn the call over to Ilan Daskal, our Executive Vice President and Chief Financial Officer.

Ilan Daskal Thank you, Rowan. Good afternoon. Thank you all for joining us, and we hope that you and your families are well and staying healthy during these challenging times. Before I begin the detailed first quarter discussion, I would like to ask Andy Lust, our Chief Operating Officer, to provide an update on BioRed's operations in light of the current pandemic-related environment that we are experiencing globally. Andy?